Pharmaceuticals & Therapeutics

PAQ Therapeutics advances its pan-KRAS degrader into human trials, backed by a $77M funding round, offering new hope for notoriously tough cancers.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

With two major trial results looming, Zura Bio appoints Sandeep Kulkarni, who led Tourmaline to a Novartis sale, to navigate its high-stakes future.

A new journal issue reveals how venture capital, advanced clinical insights, and patient-centered drug design are creating a new era in heart failure care.

A unique partnership between the City of Philadelphia, the Eagles, and a nonprofit is creating new hope for thousands awaiting a life-saving kidney transplant.

With a $150M+ capital raise and a top cancer immunologist on board, the T1D Fund is making a strategic play to shift from managing T1D to curing it.

With $35.1M in new funding, Infinitopes is launching a human trial for its AI-designed vaccine aimed at preventing oesophageal cancer recurrence.

A clinical trial for D-Serine begins in Norway, testing a novel approach that could finally slow or halt the progression of Parkinson's disease.

Machina Medical's novel hydrogel barrier, MFUSE, gains FDA clearance, promising to control severe bleeding in seconds and disrupt the hemostasis market.

The Canadian fertility network appoints former CFO Heather Stark as its first female CEO, signaling a strategic shift toward operational excellence and growth.

Veteran drug discoverer Dr. Adam Davenport joins as CSO, bringing expertise in cutting-edge modalities to accelerate client pipelines in a competitive market.

Advicenne's novel therapy for distal Renal Tubular Acidosis is under FDA review, potentially bringing the first approved treatment to thousands in the U.S.

Corvus Pharmaceuticals is set to unveil pivotal early data for its novel eczema drug, soquelitinib, a moment analysts call a critical milestone.

The deal combines Apollo Care's tech platform with eStrat's copay expertise, aiming to streamline drug access and boost pharma's bottom line.

A new partnership aims to revolutionize chronic care by letting patients self-administer large-volume biologics safely in their own homes.

A landmark Nature Medicine publication for OrsoBio's TLC-2716 offers new hope for millions suffering from severe lipid and liver disorders.

In a strategic move to enhance domestic drug production, Agno Pharma has acquired a key Oregon manufacturing site, signaling major industry consolidation.

The pet nutrition giant previews a breakthrough feline diabetes diet, home care kits, and a fresh food line, signaling a strategic shift in pet healthcare.

With a new $16.5M loan, Ocular Science is poised to expand its role in compounded eye medications, meeting the needs of an aging population.

Backed by Canada's life sciences engine adMare, new biotech firm Ocythera is advancing a unique non-retinoid therapy for debilitating bone disorders.